Literature DB >> 28659503

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.

Lukas Bubendorf1, Sylvie Lantuejoul2,3, Adrianus J de Langen4, Erik Thunnissen5.   

Abstract

The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. For diagnostic purposes on small samples, additional stains are frequently required to distinguish between squamous cell carcinoma and adenocarcinoma. Subsequently, for advanced nonsquamous cell nonsmall cell lung carcinoma (NSCLC) patients, predictive analyses on epidermal growth factor receptor, anaplastic lymphoma kinase and ROS1 are required. In NSCLCs negative for these biomarkers, programmed death ligand-1 immunohistochemistry is performed. Small samples (biopsy and cytology) require "tissue" management, which is best achieved by the interaction of all physicians involved.
Copyright ©ERS 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28659503     DOI: 10.1183/16000617.0007-2017

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  21 in total

Review 1.  Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges.

Authors:  Sule Canberk; Marianne Engels
Journal:  Virchows Arch       Date:  2021-01-03       Impact factor: 4.064

Review 2.  [Histology, cytology and molecular diagnostics of lung cancer].

Authors:  T Mairinger
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

3.  Efficacy and safety of crizotinib plus bevacizumab in ALK/ROS-1/c-MET positive non-small cell lung cancer: an open-label, single-arm, prospective observational study.

Authors:  Ziwei Huang; Qi Xiong; Zhi Cui; Haitao Tao; Sujie Zhang; Lijie Wang; Pengfei Cui; Shixue Chen; Di Huang; Bo Yang; Yi Hu
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

4.  Inferring gene expression from cell-free DNA fragmentation profiles.

Authors:  Mohammad Shahrokh Esfahani; Emily G Hamilton; Mahya Mehrmohamadi; Barzin Y Nabet; Stefan K Alig; Daniel A King; Chloé B Steen; Charles W Macaulay; Andre Schultz; Monica C Nesselbush; Joanne Soo; Joseph G Schroers-Martin; Binbin Chen; Michael S Binkley; Henning Stehr; Jacob J Chabon; Brian J Sworder; Angela B-Y Hui; Matthew J Frank; Everett J Moding; Chih Long Liu; Aaron M Newman; James M Isbell; Charles M Rudin; Bob T Li; David M Kurtz; Maximilian Diehn; Ash A Alizadeh
Journal:  Nat Biotechnol       Date:  2022-03-31       Impact factor: 68.164

5.  Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation.

Authors:  Sang Hoon Lee; Eun Young Kim; Arum Kim; Yoon Soo Chang
Journal:  Cancer Biol Ther       Date:  2020-06-16       Impact factor: 4.742

6.  Current perspective on the diagnosis of malignant pleural effusion.

Authors:  Jun Hyeok Lim; Jeong-Seon Ryu
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

Review 7.  Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Authors:  Véronique Hofman; Sandra Lassalle; Coraline Bence; Elodie Long-Mira; Sacha Nahon-Estève; Simon Heeke; Virginie Lespinet-Fabre; Catherine Butori; Marius Ilié; Paul Hofman
Journal:  Cancers (Basel)       Date:  2018-03-13       Impact factor: 6.639

Review 8.  Lung cancer biomarker testing: perspective from Europe.

Authors:  Erik Thunnissen; Birgit Weynand; Dalma Udovicic-Gagula; Luka Brcic; Malgorzata Szolkowska; Paul Hofman; Silvana Smojver-Ježek; Sisko Anttila; Fiorella Calabrese; Izidor Kern; Birgit Skov; Sven Perner; Vibeke G Dale; Zivka Eri; Alex Haragan; Diana Leonte; Lina Carvallo; Spasenja Savic Prince; Siobhan Nicholson; Irene Sansano; Ales Ryska
Journal:  Transl Lung Cancer Res       Date:  2020-06

Review 9.  Molecular Testing on Cytology for Gene Fusion Detection.

Authors:  Fernando Schmitt; Alessia Di Lorito; Philippe Vielh
Journal:  Front Med (Lausanne)       Date:  2021-07-06

10.  EGFR mutation status yield from bronchoalveolar lavage in patients with primary pulmonary adenocarcinoma compared to a venous blood sample and tissue biopsy.

Authors:  Nikolay Yanev; Evgeni Mekov; Dinko Valev; Georgi Yankov; Vladimir Milanov; Stoyan Bichev; Natalia Gabrovska; Dimitar Kostadinov
Journal:  PeerJ       Date:  2021-05-14       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.